RedHill Biopharma Wraps Up Recruitment for Phase 3 Trial of RHB-104 for Crohn’s

RedHill Biopharma Wraps Up Recruitment for Phase 3 Trial of RHB-104 for Crohn’s
RedHill Biopharma has finished recruiting the 331 participants it wanted for a Phase 3 clinical trial of RHB-104 as a treatment for Crohn’s disease. About two-thirds of the participants have already completed the study, the company announced. RHB-104 is an oral antibiotic combination therapy with potent anti-bacterial and anti-inflammatory properties. It is based on the premise that a bacteria causes

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *